Announcing the launch of Breakthroughs Today, Cures Tomorrow, our 20th anniversary campaign!
Chimeric Therapeutics has reported that a neuroendocrine cancer patient in the Phase 1 clinical trial of CAR T cell therapy has experienced tumor shrinkage. In
By Anna Greene, PhD, NETRF Chief Scientific Officer NETRF-funded scientists uncover how oxygen levels shape tumor behavior and expose new treatment opportunities for pheochromocytomas and
By Anna Greene, PhD, NETRF Chief Scientific Officer Neuroendocrine cancers, such as neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs), are rare and complex. That makes
Early clinical trial results show that AlphaMedix™ (212Pb-DOTAMTATE), an investigational targeted alpha therapy, achieved all of its main goals and produced clinically meaningful benefits for
By Anne-Marie Green, Director of Digital Communications We recently spoke with Burt Rosen, who was diagnosed with both an advanced PNET (Pancreatic Neuroendocrine Tumor) and
This is your opportunity to be part of a global effort to improve neuroendocrine cancer care. The 2nd Survey of Challenges in Access to Diagnostics and Treatment for
At the Neuroendocrine Tumor Research Foundation (NETRF), we are dedicated to transforming the future of neuroendocrine cancer care. As the world’s leading funder of neuroendocrine
By Elyse Gellerman, CEO Representatives from 25 neuroendocrine cancer advocacy groups gathered earlier this month in Sofia, Bulgaria, for the 13th INCA (International Neuroendocrine Cancer
By Anna Greene, PhD, NETRF Director of Research A major new study published in JAMA Network Open by Arvind Dasari, MD, MS, and colleagues provides
By Anna Greene, PhD, NETRF Director of Research We’re excited to share insights from a new ENETS (European Neuroendocrine Tumor Society) position statement, published in